Navigation Links
Investigational Diabetes Drug May Also Have Future As Treatment for Parkinson's Disease
Date:9/19/2013

KALAMAZOO, Mich., Sept. 19, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the presentation of new data showing an investigational drug being studied to treat diabetes, MSDC-0160, had a protective effect  on nerve cells in the brain that control movement, balance and walking.  These results in laboratory and animal models of Parkinson's disease suggest MSDC-0160 may have the potential to modify the course of Parkinson's disease. The Company is preparing for the start of clinical trials, which could begin in late 2014.

These results were generated in collaboration with Patrik Brundin, MD, PhD, Head of the Laboratory of Translational Parkinson's Disease Research and Director of the Center for Neurodegenerative Science at the Van Andel Institute (VAI). The data were presented by post-doctoral fellow Anamitra Ghosh at the "Grand Challenges in Parkinson's Disease" symposium, which is being convened September 18 – 19 at VAI (Grand Rapids, MI).

First in Class
MSDC-0160 is the first in a new class of insulin sensitizers called mTOT Modulators™, which appear to exert their therapeutic effects through a new drug target located in the inner mitochondrial membrane. MSDC-0160 has been shown to be well-tolerated and no significant safety issues were noted in studies in patients with type 2 diabetes or elderly patients with dementia due to Alzheimer's disease. In a Phase 2b clinical trial in 258 patients with type 2 diabetes, MSDC-0160 was shown to lower hemoglobin A1c significantly without the side effect profile of currently marketed insulin sensitizers, which are PPARg agonists. In a recently completed Phase 2a trial in 29 patients with dementia due to Alzheimer's disease (NCT01374438), MSDC-0160 was shown to maintain or increase glucose metabolism in the brain, as measured by FDG-PET imaging, in predefined regions of interest in the brain associated with cognitive decline.

Mitochondria and Parkinson's Disease
Parkinson's disease is a chronic, degenerative neurological disorder that affects an estimated one million people in the United States, and more than five million worldwide. Impaired mitochondrial function has been implicated in the development of Parkinson's disease. Mitochondria are the "power plants" of the cell, generating energy needed for cell activity. Therapies that improve mitochondrial function may have the potential to slow the progression of the disease.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute is an independent research organization dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. This is accomplished through the work of over 200 researchers in more than 20 on-site laboratories and in collaborative partnerships that span the globe. Find out more about Van Andel Institute or donate by visiting www.vai.org

About Patrik Brundin, MD, PhD
Patrik Brundin, M.D., Ph.D. Brundin has more than 30 years of experience with neurodegenerative diseases, Parkinson's disease pathogenesis, and therapeutic neural grafting into people with Parkinson's disease. He is one of the top cited researchers in the field of neuroscience with around 300 publications on Parkinson's disease and related topics. In addition to managing laboratories at VAI and at Lund University, Sweden, he is the co-editor in chief of the Journal of Parkinson's Disease and has coordinated multiple international research programs.  


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lillys Investigational GLP-1 Receptor Agonist, Dulaglutide, Showed Superior Glycemic Control Versus Comparators in Patients with Type 2 Diabetes
2. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
3. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
4. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
5. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
6. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
7. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
8. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
9. Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
10. Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced
11. Research Report on Chinas Diabetes Drug Market, 2013-2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... 2016   ViaCyte, Inc. , a privately-held regenerative ... replacement therapy for the treatment of diabetes in clinical-stage ... Meeting.  ISSCR 2016, the Global Stem Cell Event, is ... in San Francisco.    ... follows:Event: , Focus Session: Tools for Basic and Applied ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):